The Sequential Expression Profiles of Growth Factors from Osteroprogenitors to Osteoblasts<i>In Vitro</i>

Huang, Zhu; Nelson, Ehren R.; Smith, Robert L.; Goodman, Stuart B.

doi:10.1089/ten.2006.0423

Cited by 178 publications

(176 citation statements)

References 73 publications

Supporting

Mentioning

164

Contrasting

Unclassified

Order By: Relevance

“…The release profile of OC demonstrated a detectable level at Day 15. OC levels remained high and increased continuously after Day 20, which agrees with previous experiments using similar conditions on culture plates alone [12].…”

Section: Resultssupporting

confidence: 91%

“…Various growth factors, such as IGF-1 [30], IL-6 [32], BMP-2 [35,36], and CDMP-1 [31], were reported to enhance the effects of OP-1. Two recent studies reported FGF-2 also inhibited the stimulatory effects of OP-1 [4,14]; however, we found neither synergic nor antagonistic effects between OP-1 and FGF-2 in the present experiment, which is consistent with a previous in vivo study [12].…”

Section: Discussionsupporting

confidence: 91%

“…While different experimental models and drug release schedules may explain some of the findings, the timing of adding FGF-2 may be one of the key factors related to the outcome. FGF-2 from bone marrow cells cultured in osteogenic media is expressed only in the stage of differentiation [12]. Therefore, the continuous addition of FGF-2 in this experiment appears to prevent or delay the osteoprogenitor cells from entering the differentiation stage.…”

Section: Discussionmentioning

confidence: 81%

“…In vitro and in vivo studies have confirmed bone-specific growth factors exhibit autocrine and paracrine effects on the proliferation, differentiation, and maturation of osteoprogenitor cells [12]. Fibroblast growth factor basic (FGF-2) is expressed in mesenchymal cells, as well as mature osteoblasts, and is stored in the extracellular matrix [11].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Controlled Release of Growth Factors on Allograft Bone in vitro

Huang

Ryu

Ren

et al. 2008

Clin Orthop Relat Res

Self Cite

View full text Add to dashboard Cite

Allografts are important alternatives to autografts for treating defects after major bone loss. Bone growth factors have both local autocrine and paracrine effects and regulate the growth, proliferation, and differentiation of osteoprogenitor cells. To study the effects of prolonged, continuous, local delivery of growth factors on bone growth, we developed a new microelectromechanical system (MEMS) drug delivery device. Bone marrow cells from mice were seeded on mouse allograft discs and cultured in osteogenic media with osteogenic protein 1 (OP-1) and/or basic fibroblast growth factor (FGF-2) delivered from MEMS devices for 6 weeks. We monitored bone formation by changes of bone volume using micro-CT scanning and release of osteocalcin using ELISA. The data suggest the MEMS devices delivered constant concentrations of OP-1 and FGF-2 to the media. Bone marrow cells grew on the allografts and increased bone volume. Addition of OP-1 increased bone formation whereas FGF-2 decreased bone formation. Local delivery of growth factors over a prolonged period modulated the differentiation of osteoprogenitor cells on allograft bone.

show abstract

Section: Resultssupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 81%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Controlled Release of Growth Factors on Allograft Bone in vitro

Huang

Ryu

Ren

et al. 2008

Clin Orthop Relat Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent study showed a decrease in IGF-1 mRNA levels parallel to the increase in the differentiation of the osteoblasts (26). Therefore, we can hypothesize that the gene expression of IGF-1 may be influenced by the composition of the culture medium and subsequently by the level of cell maturation.…”

Section: Discussionmentioning

confidence: 88%

Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone

Sanchez

Deberg

Bellahcène

et al. 2008

Arthritis & Rheumatism

145

107

View full text Add to dashboard Cite

Objective. To determine the phenotype of osteoblasts from the sclerotic zones of human osteoarthritic (OA) subchondral bone.Methods. Human osteoblasts were isolated from sclerotic or nonsclerotic areas of subchondral bone and cultured for 14 days in monolayer. The expression of 14 genes was investigated by real-time reverse transcriptionpolymerase chain reaction. The activities of alkaline phosphatase (AP) and transglutaminases (TGases) were quantified by enzymatic assays. C-terminal type I procollagen propeptide (CPI), interleukin-1␤ (IL-1␤), IL-6, IL-8, transforming growth factor ␤1 (TGF␤1), osteocalcin (OC), and osteopontin (OPN) were assayed in the culture medium by immunoassay.Results. Gene expression levels of matrix metalloproteinase 13, COL1A1 and COL1A2, OPN, tissuenonspecific AP, OC, vascular endothelial growth factor, ANKH, TGase 2, factor XIIIA, and dentin matrix protein 1 were significantly up-regulated in sclerotic osteoblasts compared with nonsclerotic osteoblasts. In contrast, parathyroid hormone receptor gene expression was depressed in sclerotic osteoblasts, but bone sialoprotein levels were unchanged. The activities of AP and TGases were increased in sclerotic osteoblasts, while matrix mineralization, revealed by alizarin red staining, was decreased. In parallel, protein synthesis of CPI, OC, OPN, IL-6, IL-8, and TGF␤1 was significantly higher in sclerotic osteoblasts than in nonsclerotic osteoblasts, while IL-1␤ production was similar in both groups.Conclusion. These findings contribute to a better understanding of the mechanisms involved in subchondral bone sclerosis and identify osteoblasts with an altered phenotype as a potential target for future OA therapies.Osteoarthritis (OA) is a common leading cause of disability in the elderly that is characterized by cartilage degradation, synovium and tendon inflammation, muscle weakness, osteophyte formation, and subchondral bone plate thickening (1). Although it is not yet clear whether it precedes (2-4) or occurs subsequently to cartilage damage (5-7), subchondral bone remodeling is an important feature in the pathophysiology of OA and is characterized by osteoid substance accumulation, decreased mineralization, and increased amounts of type I homotrimer (8). It is speculated that subchondral bone remodeling is linked to cartilage degradation, not only by modifying the mechanical properties of the subchondral bone (9) but also by releasing factors that may influence cartilage metabolism (10,11). Thus, the understanding of the mechanisms leading to bone sclerosis is of the utmost importance in the treatment of OA.Indeed, previous studies have demonstrated that some osteoblasts are phenotypically different and may produce increased levels of alkaline phosphatase (AP), osteocalcin (OC), transforming growth factor ␤1 (TGF␤1), insulin-like growth factor 1 (IGF-1), and urokinase plasminogen activator, while levels of IGF binding proteins 3, 4, and 5 are lower and plasminogen activator inhibitor 1 and interleukin-1␤ (IL-1␤) levels remain unchanged (12...

show abstract

Silk Fibroin 3D Microparticle Scaffolds with Bioactive Ceramics: Chemical, Mechanical, and Osteoregenerative Characteristics

et al. 2020

View full text Add to dashboard Cite

Bone regeneration in large bone cavities presents a major challenge. These bony voids are either filled with an autograft/ allograft (patient's own bone from another anatomical location or cadaveric bone, respectively), or synthetic bone graft substitute called "bone void filler." Autografts are the 'gold standard' for bone grafting, but have inherent limitations of donor site morbidity and limited supply. [1] More recently, synthetic ceramics have shown promise for this application of bone void filling because of their chemical similarity to ceramics present in natural bone. Commonly used bioceramics include hydroxyapatite (HA), beta tricalcium phosphate (TCP), and more recently calcium sulfate (CaS). These materials are biocompatible, and support cell adhesion, proliferation, and growth of bone cells. Although these bioceramics are used as bone void fillers, they have certain limitations: they are intrinsically brittle and lack the required mechanical properties. Also, some of them have faster bioresorption rate (e.g., CaS and TCP), whereas others do not completely bioresorb (e.g., HA). In this context, to achieve native bone-like properties, current trend in bone tissue engineering (BTE) is to use a composite of bioceramic and a biocompatible polymer. [2,3] Silk fibroin (SF)-a natural biopolymerhas come up as potential candidate for BTE, owing to its biocompatibility, mechanical properties, tunable biodegradation rate, and ease of processability. The silk from the Bombyx mori silkworm, commonly known as a mulberry silkworm, can be produced with good quality in large quantities. [4-6] Efficacy of SF-based biomaterials has been proven in various tissue regeneration models. [7,8] SF can be easily modulated to obtain required functionality and different forms. [9,10] Different SF-based biomaterials including SF films, [11] SF-3D scaffold, [12,13] and SF-reinforced biomaterials [14] have proven to be successful for bone regeneration purpose. We have earlier reported a method to prepare silk fibroin microparticle scaffolds that have shown a high potential in BTE. [12] These SF microparticle scaffolds have excellent mechanical properties, pore interconnectivity, and a superior ability to promote osteoregeneration. The objective of this work was to prepare regenerated silk fibroin (RSF) microparticle scaffolds filled with nano-HA or CaS. [12,13] The addition of these fillers would further enhance the mechanical properties of these scaffolds and would thereby contribute toward the osteoregenerative potential. We compare and evaluate the performance of these microparticles and scaffolds vis-à-vis pure SF scaffolds. We have characterized the microparticles and their scaffolds for the

show abstract

The Sequential Expression Profiles of Growth Factors from Osteroprogenitors to OsteoblastsIn Vitro

Cited by 178 publications

References 73 publications

Controlled Release of Growth Factors on Allograft Bone in vitro

Controlled Release of Growth Factors on Allograft Bone in vitro

Phenotypic characterization of osteoblasts from the sclerotic zones of osteoarthritic subchondral bone

Silk Fibroin 3D Microparticle Scaffolds with Bioactive Ceramics: Chemical, Mechanical, and Osteoregenerative Characteristics

Contact Info

Product

Resources

About